Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2023

Open Access 01-12-2023 | Influenza Virus | Review

Immune response in influenza virus infection and modulation of immune injury by viral neuraminidase

Authors: Hongyu Jiang, Zongde Zhang

Published in: Virology Journal | Issue 1/2023

Login to get access

Abstract

Influenza A viruses cause severe respiratory illnesses in humans and animals. Overreaction of the innate immune response to influenza virus infection results in hypercytokinemia, which is responsible for mortality and morbidity. The influenza A virus surface glycoprotein neuraminidase (NA) plays a vital role in viral attachment, entry, and virion release from infected cells. NA acts as a sialidase, which cleaves sialic acids from cell surface proteins and carbohydrate side chains on nascent virions. Here, we review progress in understanding the role of NA in modulating host immune response to influenza virus infection. We also discuss recent exciting findings targeting NA protein to interrupt influenza-induced immune injury.
Literature
1.
Javanian M, Barary M, Ghebrehewet S, Koppolu V, et al. A brief review of influenza virus infection. J Med Virol. 2021;93(8):4638–46.PubMed
2.
Gaitonde DY, Moore FC, Morgan MK. Influenza: diagnosis and treatment. Am Fam Phys. 2019;100(12):751–8.
3.
Bridges CB, Kuehnert MJ, Hall CB. Transmission of influenza: implications for control in health care settings. Clin Infect Dis. 2003;37(8):1094–101.PubMed
4.
Tamerius J, Nelson MI, Zhou SZ, Viboud C, et al. Global influenza seasonality: reconciling patterns across temperate and tropical regions. Environ Health Perspect. 2011;119(4):439–45.PubMed
5.
Kalil AC, Thomas PG. Influenza virus-related critical illness: pathophysiology and epidemiology. Crit Care. 2019;23(1):258.PubMedPubMedCentral
6.
7.
Zhai SL, Zhang H, Chen SN, Zhou X, et al. Influenza D virus in animal species in Guangdong Province, Southern China. Emerg Infect Dis. 2017;23(8):1392–6.PubMedPubMedCentral
8.
Centers for Disease C, Prevention. Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1)—United States, May-August 2009. MMWR Morb Mortal Wkly Rep. 2009;58(38):1071–4.
9.
Shaw ML, Stone KL, Colangelo CM, Gulcicek EE, et al. Cellular proteins in influenza virus particles. PLoS Pathog. 2008;4(6):e1000085.PubMedPubMedCentral
10.
Hutchinson EC, Charles PD, Hester SS, Thomas B, et al. Conserved and host-specific features of influenza virion architecture. Nat Commun. 2014;5:4816.PubMed
11.
Tate MD, Job ER, Deng YM, Gunalan V, et al. Playing hide and seek: how glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection. Viruses. 2014;6(3):1294–316.PubMedPubMedCentral
12.
Reading PC, Tate MD, Pickett DL, Brooks AG. Glycosylation as a target for recognition of influenza viruses by the innate immune system. Adv Exp Med Biol. 2007;598:279–92.PubMed
13.
Tumpey TM, Maines TR, Van Hoeven N, Glaser L, et al. A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission. Science. 2007;315(5812):655–9.PubMed
14.
McCrone JT, Woods RJ, Martin ET, Malosh RE, et al. Stochastic processes constrain the within and between host evolution of influenza virus. Elife. 2018;7:e35962.PubMedPubMedCentral
15.
Dadonaite B, Gilbertson B, Knight ML, Trifkovic S, et al. The structure of the influenza A virus genome. Nat Microbiol. 2019;4(11):1781–9.PubMedPubMedCentral
16.
Sanders CJ, Vogel P, McClaren JL, Bajracharya R, et al. Compromised respiratory function in lethal influenza infection is characterized by the depletion of type I alveolar epithelial cells beyond threshold levels. Am J Physiol Lung Cell Mol Physiol. 2013;304(7):L481–8.PubMedPubMedCentral
17.
Short KR, Kroeze E, Fouchier RAM, Kuiken T. Pathogenesis of influenza-induced acute respiratory distress syndrome. Lancet Infect Dis. 2014;14(1):57–69.PubMed
18.
Rust MJ, Lakadamyali M, Zhang F, Zhuang X. Assembly of endocytic machinery around individual influenza viruses during viral entry. Nat Struct Mol Biol. 2004;11(6):567–73.PubMedPubMedCentral
19.
Rossman JS, Lamb RA. Influenza virus assembly and budding. Virology. 2011;411(2):229–36.PubMed
20.
Ohuchi M, Asaoka N, Sakai T, Ohuchi R. Roles of neuraminidase in the initial stage of influenza virus infection. Microbes Infect. 2006;8(5):1287–93.PubMed
21.
McAuley JL, Gilbertson BP, Trifkovic S, Brown LE, et al. Influenza virus neuraminidase structure and functions. Front Microbiol. 2019;10:39.PubMedPubMedCentral
22.
Brown EG. Influenza virus genetics. Biomed Pharmacother. 2000;54(4):196–209.PubMed
23.
Li L, Dai S, Gao GF, Wang J. Lattice-translocation defects in specific crystals of the catalytic head domain of influenza neuraminidase. Acta Crystallogr D Struct Biol. 2020;76(Pt 11):1057–64.PubMed
24.
Ellis D, Lederhofer J, Acton OJ, Tsybovsky Y, et al. Structure-based design of stabilized recombinant influenza neuraminidase tetramers. Nat Commun. 2022;13(1):1825.PubMedPubMedCentral
25.
Einav T, Gentles LE, Bloom JD. SnapShot: influenza by the numbers. Cell. 2020;182(2):532-e1.PubMed
26.
Jin H, Leser GP, Zhang J, Lamb RA. Influenza virus hemagglutinin and neuraminidase cytoplasmic tails control particle shape. EMBO J. 1997;16(6):1236–47.PubMedPubMedCentral
27.
Barman S, Adhikary L, Chakrabarti AK, Bernas C, et al. Role of transmembrane domain and cytoplasmic tail amino acid sequences of influenza a virus neuraminidase in raft association and virus budding. J Virol. 2004;78(10):5258–69.PubMedPubMedCentral
28.
Kundu A, Avalos RT, Sanderson CM, Nayak DP. Transmembrane domain of influenza virus neuraminidase, a type II protein, possesses an apical sorting signal in polarized MDCK cells. J Virol. 1996;70(9):6508–15.PubMedPubMedCentral
29.
Krogh A, Larsson B, von Heijne G, Sonnhammer EL. Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J Mol Biol. 2001;305(3):567–80.PubMed
30.
Moller S, Croning MD, Apweiler R. Evaluation of methods for the prediction of membrane spanning regions. Bioinformatics. 2001;17(7):646–53.PubMed
31.
Air GM. Influenza neuraminidase. Influenza Other Respir Viruses. 2012;6(4):245–56.PubMed
32.
Kumari K, Gulati S, Smith DF, Gulati U, et al. Receptor binding specificity of recent human H3N2 influenza viruses. Virol J. 2007;4:42.PubMedPubMedCentral
33.
Chandrasekaran A, Srinivasan A, Raman R, Viswanathan K, et al. Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin. Nat Biotechnol. 2008;26(1):107–13.PubMed
34.
Sun Y, Tan Y, Wei K, Sun H, et al. Amino acid 316 of hemagglutinin and the neuraminidase stalk length influence virulence of H9N2 influenza virus in chickens and mice. J Virol. 2013;87(5):2963–8.PubMedPubMedCentral
35.
Wang X, Zeng Z, Zhang Z, Zheng Y, et al. The appropriate combination of hemagglutinin and neuraminidase prompts the predominant H5N6 highly pathogenic avian influenza virus in birds. Front Microbiol. 2018;9:1088.PubMedPubMedCentral
36.
Burmeister WP, Ruigrok RW, Cusack S. The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J. 1992;11(1):49–56.PubMedPubMedCentral
37.
Xu X, Zhu X, Dwek RA, Stevens J, et al. Structural characterization of the 1918 influenza virus H1N1 neuraminidase. J Virol. 2008;82(21):10493–501.PubMedPubMedCentral
38.
Russell RJ, Haire LF, Stevens DJ, Collins PJ, et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature. 2006;443(7107):45–9.PubMed
39.
Zhu X, Turner HL, Lang S, McBride R, et al. Structural basis of protection against H7N9 influenza virus by human anti-N9 neuraminidase antibodies. Cell Host Microbe. 2019;26(6):729–38.PubMedPubMedCentral
40.
41.
Wu R, Zhang H, Yang K, Liang W, et al. Multiple amino acid substitutions are involved in the adaptation of H9N2 avian influenza virus to mice. Vet Microbiol. 2009;138(1–2):85–91.PubMed
42.
Zhang Z, Hu S, Li Z, Wang X, et al. Multiple amino acid substitutions involved in enhanced pathogenicity of LPAI H9N2 in mice. Infect Genet Evol. 2011;11(7):1790–7.PubMed
43.
Kim H, Webster RG, Webby RJ. Influenza virus: dealing with a drifting and shifting pathogen. Viral Immunol. 2018;31(2):174–83.PubMed
44.
Morens DM, Taubenberger JK. Making universal influenza vaccines: lessons from the 1918 pandemic. J Infect Dis. 2019;219(Suppl_1):S5–13.PubMed
45.
Heaton NS, Sachs D, Chen CJ, Hai R, et al. Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins. Proc Natl Acad Sci U S A. 2013;110(50):20248–53.PubMedPubMedCentral
46.
Das SR, Hensley SE, Ince WL, Brooke CB, et al. Defining influenza A virus hemagglutinin antigenic drift by sequential monoclonal antibody selection. Cell Host Microbe. 2013;13(3):314–23.PubMedPubMedCentral
47.
Sandbulte MR, Westgeest KB, Gao J, Xu X, et al. Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses. Proc Natl Acad Sci U S A. 2011;108(51):20748–53.PubMedPubMedCentral
48.
Sandbulte MR, Gao J, Straight TM, Eichelberger MC. A miniaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics-derived antigens. Influenza Other Respir Viruses. 2009;3(5):233–40.PubMedPubMedCentral
49.
Zeller MA, Chang J, Vincent AL, Gauger PC, et al. Spatial and temporal coevolution of N2 neuraminidase and H1 and H3 hemagglutinin genes of influenza A virus in US swine. Virus Evol. 2021;7(2):veab090.PubMedPubMedCentral
50.
Kirkpatrick Roubidoux E, McMahon M, Carreno JM, Capuano C, et al. Identification and characterization of novel antibody epitopes on the N2 neuraminidase. mSphere. 2021;6(1):e00958-20.PubMedPubMedCentral
51.
Benton DJ, Martin SR, Wharton SA, McCauley JW. Biophysical measurement of the balance of influenza a hemagglutinin and neuraminidase activities. J Biol Chem. 2015;290(10):6516–21.PubMedPubMedCentral
52.
Arai Y, Elgendy EM, Daidoji T, Ibrahim MS, et al. H9N2 influenza virus infections in human cells require a balance between neuraminidase sialidase activity and hemagglutinin receptor affinity. J Virol. 2020;94(18):10–1128.
53.
Benton DJ, Gamblin SJ, Rosenthal PB, Skehel JJ. Structural transitions in influenza haemagglutinin at membrane fusion pH. Nature. 2020;583(7814):150–3.PubMedPubMedCentral
54.
de Vries E, Du W, Guo H, de Haan CAM. Influenza A virus hemagglutinin-neuraminidase-receptor balance: preserving virus motility. Trends Microbiol. 2020;28(1):57–67.PubMed
55.
Cohen M, Zhang XQ, Senaati HP, Chen HW, et al. Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase. Virol J. 2013;10:321.PubMedPubMedCentral
56.
Byrd-Leotis L, Cummings RD, Steinhauer DA. The interplay between the host receptor and influenza virus hemagglutinin and neuraminidase. Int J Mol Sci. 2017;18(7):1541.PubMedPubMedCentral
57.
Creytens S, Pascha MN, Ballegeer M, Saelens X, et al. Influenza neuraminidase characteristics and potential as a vaccine target. Front Immunol. 2021;12:786617.PubMedPubMedCentral
58.
59.
Julkunen I, Melen K, Nyqvist M, Pirhonen J, et al. Inflammatory responses in influenza A virus infection. Vaccine. 2000;19(Suppl 1):S32-7.PubMed
60.
Fitzgerald-Bocarsly P, Dai J, Singh S. Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev. 2008;19(1):3–19.PubMedPubMedCentral
61.
Saenz RA, Quinlivan M, Elton D, Macrae S, et al. Dynamics of influenza virus infection and pathology. J Virol. 2010;84(8):3974–83.PubMedPubMedCentral
62.
Gu Y, Hsu AC, Pang Z, Pan H, et al. Role of the innate cytokine storm induced by the influenza A virus. Viral Immunol. 2019;32(6):244–51.PubMed
63.
Liu Q, Zhou YH, Yang ZQ. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol. 2016;13(1):3–10.PubMed
64.
Teijaro JR. The role of cytokine responses during influenza virus pathogenesis and potential therapeutic options. Curr Top Microbiol Immunol. 2015;386:3–22.PubMed
65.
66.
Li X, Shao M, Zeng X, Qian P, et al. Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy. Signal Transduct Target Ther. 2021;6(1):367.PubMedPubMedCentral
67.
68.
Karki R, Kanneganti TD. The “cytokine storm”: molecular mechanisms and therapeutic prospects. Trends Immunol. 2021;42(8):681–705.PubMedPubMedCentral
69.
70.
Le VB, Schneider JG, Boergeling Y, Berri F, et al. Platelet activation and aggregation promote lung inflammation and influenza virus pathogenesis. Am J Respir Crit Care Med. 2015;191(7):804–19.PubMed
71.
Joseph C, Togawa Y, Shindo N. Bacterial and viral infections associated with influenza. Influenza Other Respir Viruses. 2013;7(Suppl 2):105–13.PubMedPubMedCentral
72.
Zhou Y, Fu X, Liu X, Huang C, et al. Use of corticosteroids in influenza-associated acute respiratory distress syndrome and severe pneumonia: a systemic review and meta-analysis. Sci Rep. 2020;10(1):3044.PubMedPubMedCentral
73.
Klomp M, Ghosh S, Mohammed S, Nadeem KM. From virus to inflammation, how influenza promotes lung damage. J Leukoc Biol. 2021;110(1):115–22.PubMed
74.
Keef E, Zhang LA, Swigon D, Urbano A, et al. Discrete dynamical modeling of influenza virus infection suggests age-dependent differences in immunity. J Virol. 2017;91(23):10–1128.
75.
Tanner AR, Dorey RB, Brendish NJ, Clark TW. Influenza vaccination: protecting the most vulnerable. Eur Respir Rev. 2021;30(159):200258.PubMedPubMedCentral
76.
Thompson WW, Shay DK, Weintraub E, Brammer L, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292(11):1333–40.PubMed
77.
Jefferson T, Jones MA, Doshi P, Del Mar CB, et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database Syst Rev. 2014;4:CD008965.
78.
Coates BM, Staricha KL, Koch CM, Cheng Y, et al. Inflammatory monocytes drive influenza A virus-mediated lung injury in juvenile mice. J Immunol. 2018;200(7):2391–404.PubMed
79.
Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2018;2:CD004879.PubMed
80.
Lim HK, Huang SXL, Chen J, Kerner G, et al. Severe influenza pneumonitis in children with inherited TLR3 deficiency. J Exp Med. 2019;216(9):2038–56.PubMedPubMedCentral
81.
Hulme KD, Noye EC, Short KR, Labzin LI. Dysregulated inflammation during obesity: driving disease severity in influenza virus and SARS-CoV-2 infections. Front Immunol. 2021;12:770066.PubMedPubMedCentral
82.
83.
Shaikh S, Haas K, Beck M, Teague H. The effects of diet-induced obesity on B cell function. Clin Exp Immunol. 2015;179(1):90–9.PubMed
84.
Bhattacharya I, Ghayor C, Perez Dominguez A, Weber FE. From influenza virus to novel corona virus (SARS-CoV-2)—the contribution of obesity. Front Endocrinol (Lausanne). 2020;11:556962.PubMed
85.
Brooke CB, Ince WL, Wrammert J, Ahmed R, et al. Most influenza a virions fail to express at least one essential viral protein. J Virol. 2013;87(6):3155–62.PubMedPubMedCentral
86.
Kosik I, Yewdell JW. Influenza hemagglutinin and neuraminidase: Yin(–)Yang Proteins coevolving to thwart immunity. Viruses. 2019;11(4):346.PubMedPubMedCentral
87.
McCraw DM, Gallagher JR, Torian U, Myers ML, et al. Structural analysis of influenza vaccine virus-like particles reveals a multicomponent organization. Sci Rep. 2018;8(1):10342.PubMedPubMedCentral
88.
Smith BJ, Huyton T, Joosten RP, McKimm-Breschkin JL, et al. Structure of a calcium-deficient form of influenza virus neuraminidase: implications for substrate binding. Acta Crystallogr D Biol Crystallogr. 2006;62(Pt 9):947–52.PubMed
89.
Long JS, Mistry B, Haslam SM, Barclay WS. Host and viral determinants of influenza A virus species specificity. Nat Rev Microbiol. 2019;17(2):67–81.PubMed
90.
Li N, Parrish M, Chan TK, Yin L, et al. Influenza infection induces host DNA damage and dynamic DNA damage responses during tissue regeneration. Cell Mol Life Sci. 2015;72(15):2973–88.PubMedPubMedCentral
91.
Yip TF, Selim ASM, Lian I, Lee SM. Advancements in host-based interventions for influenza treatment. Front Immunol. 2018;9:1547.PubMedPubMedCentral
92.
Martin BE, Harris JD, Sun J, Koelle K, et al. Cellular co-infection can modulate the efficiency of influenza A virus production and shape the interferon response. PLoS Pathog. 2020;16(10):e1008974.PubMedPubMedCentral
93.
Teijaro JR, Walsh KB, Cahalan S, Fremgen DM, et al. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell. 2011;146(6):980–91.PubMedPubMedCentral
94.
Robinson KM, Kolls JK, Alcorn JF. The immunology of influenza virus-associated bacterial pneumonia. Curr Opin Immunol. 2015;34:59–67.PubMedPubMedCentral
95.
Gallucci RM, Sloan DK, Heck JM, Murray AR, et al. Interleukin 6 indirectly induces keratinocyte migration. J Invest Dermatol. 2004;122(3):764–72.PubMed
96.
97.
Crane MJ, Xu Y, Henry WL Jr, Gillis SP, et al. Pulmonary influenza A virus infection leads to suppression of the innate immune response to dermal injury. PLoS Pathog. 2018;14(8):e1007212.PubMedPubMedCentral
98.
Boniakowski AE, Kimball AS, Joshi A, Schaller M, et al. Murine macrophage chemokine receptor CCR2 plays a crucial role in macrophage recruitment and regulated inflammation in wound healing. Eur J Immunol. 2018;48(9):1445–55.PubMedPubMedCentral
99.
Voelker DR, Numata M. Phospholipid regulation of innate immunity and respiratory viral infection. J Biol Chem. 2019;294(12):4282–9.PubMedPubMedCentral
100.
Li N, Ren A, Wang X, Fan X, et al. Influenza viral neuraminidase primes bacterial coinfection through TGF-beta-mediated expression of host cell receptors. Proc Natl Acad Sci U S A. 2015;112(1):238–43.PubMed
101.
Koutsakos M, Kedzierska K, Subbarao K. Immune responses to avian influenza viruses. J Immunol. 2019;202(2):382–91.PubMed
102.
Ma C, Li Y, Zong Y, Velkov T, et al. p21 restricts influenza A virus by perturbing the viral polymerase complex and upregulating type I interferon signaling. PLoS Pathog. 2022;18(2):e1010295.PubMedPubMedCentral
103.
Liu S, Yan R, Chen B, Pan Q, et al. Influenza virus-induced robust expression of SOCS3 contributes to excessive production of IL-6. Front Immunol. 2019;10:1843.PubMedPubMedCentral
104.
Cyster JG. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol. 2005;23:127–59.PubMed
105.
Walsh KB, Teijaro JR, Wilker PR, Jatzek A, et al. Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc Natl Acad Sci U S A. 2011;108(29):12018–23.PubMedPubMedCentral
106.
Teijaro JR, Walsh KB, Rice S, Rosen H, et al. Mapping the innate signaling cascade essential for cytokine storm during influenza virus infection. Proc Natl Acad Sci U S A. 2014;111(10):3799–804.PubMedPubMedCentral
107.
Smee DF, Huffman JH, Morrison AC, Barnard DL, et al. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob Agents Chemother. 2001;45(3):743–8.PubMedPubMedCentral
108.
Jia R, Zhang J, Bertagnin C, Cherukupalli S, et al. Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity. Eur J Med Chem. 2021;212:113097.PubMed
109.
Wang HX, Zeng MS, Ye Y, Liu JY, et al. Antiviral activity of puerarin as potent inhibitor of influenza virus neuraminidase. Phytother Res. 2021;35(1):324–36.PubMed
110.
111.
Wang W, Wu J, Zhang X, Hao C, et al. Inhibition of influenza A virus infection by fucoidan targeting viral neuraminidase and cellular EGFR pathway. Sci Rep. 2017;7:40760.PubMedPubMedCentral
112.
Dormitzer PR, Galli G, Castellino F, Golding H, et al. Influenza vaccine immunology. Immunol Rev. 2011;239(1):167–77.PubMed
113.
Pliasas VC, Menne Z, Aida V, Yin JH, et al. A novel neuraminidase virus-like particle vaccine offers protection against heterologous H3N2 influenza virus infection in the porcine model. Front Immunol. 2022;13:915364.PubMedPubMedCentral
114.
Kosik I, Angeletti D, Gibbs JS, Angel M, et al. Neuraminidase inhibition contributes to influenza A virus neutralization by anti-hemagglutinin stem antibodies. J Exp Med. 2019;216(2):304–16.PubMedPubMedCentral
115.
Broecker F, Zheng A, Suntronwong N, Sun W, et al. Extending the stalk enhances immunogenicity of the influenza virus neuraminidase. J Virol. 2019;93(18):10–1128.
116.
Stadlbauer D, Zhu X, McMahon M, Turner JS, et al. Broadly protective human antibodies that target the active site of influenza virus neuraminidase. Science. 2019;366(6464):499–504.PubMedPubMedCentral
117.
Krammer F, Fouchier RAM, Eichelberger MC, Webby RJ, et al. NAction! How can neuraminidase-based immunity contribute to better influenza virus vaccines? MBio. 2018;9(2):10–128.
118.
Eichelberger MC, Wan H. Influenza neuraminidase as a vaccine antigen. Curr Top Microbiol Immunol. 2015;386:275–99.PubMed
119.
Wang Y, Lei R, Nourmohammad A, Wu NC. Antigenic evolution of human influenza H3N2 neuraminidase is constrained by charge balancing. Elife. 2021;10:e72516.PubMedPubMedCentral
120.
Liu X, Luo W, Zhang B, Lee YG, et al. Design of neuraminidase-targeted imaging and therapeutic agents for the diagnosis and treatment of influenza virus infections. Bioconjug Chem. 2021;32(8):1548–53.PubMed
121.
Strohmeier S, Amanat F, Zhu X, McMahon M, et al. A novel recombinant influenza virus neuraminidase vaccine candidate stabilized by a measles virus phosphoprotein tetramerization domain provides robust protection from virus challenge in the mouse model. MBio. 2021;12(6):e0224121.PubMed
122.
Tan J, O’Dell G, Hernandez MM, Sordillo EM, et al. Human anti-neuraminidase antibodies reduce airborne transmission of clinical influenza virus isolates in the guinea pig model. J Virol. 2022;96(2):e0142121.PubMed
123.
Strohmeier S, Amanat F, Carreno JM, Krammer F. Monoclonal antibodies targeting the influenza virus N6 neuraminidase. Front Immunol. 2022;13:944907.PubMedPubMedCentral
124.
Wong SS, DeBeauchamp J, Zanin M, Sun Y, et al. H5N1 influenza vaccine induces a less robust neutralizing antibody response than seasonal trivalent and H7N9 influenza vaccines. NPJ Vaccines. 2017;2:16.PubMedPubMedCentral
125.
Kirkpatrick Roubidoux E, Sano K, McMahon M, Carreno JM, et al. Novel epitopes of the influenza virus N1 neuraminidase targeted by human monoclonal antibodies. J Virol. 2022;96(9):e0033222.PubMed
126.
Kutkat O, Kandeil A, Moatasim Y, Elshaier Y, et al. In vitro and in vivo antiviral studies of new heteroannulated 1,2,3-triazole glycosides targeting the neuraminidase of influenza A viruses. Pharmaceuticals (Basel). 2022;15(3):351.PubMed
127.
Xiao M, Xu L, Lin D, Lian W, et al. Design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors. Eur J Med Chem. 2021;213:113161.PubMed
128.
Li Z, Ju X, Silveira PA, Abadir E, et al. CD83: activation marker for antigen presenting cells and its therapeutic potential. Front Immunol. 2019;10:1312.PubMedPubMedCentral
129.
Lechmann M, Berchtold S, Hauber J, Steinkasserer A. CD83 on dendritic cells: more than just a marker for maturation. Trends Immunol. 2002;23(6):273–5.PubMed
130.
Scholler N, Hayden-Ledbetter M, Hellstrom KE, Hellstrom I, et al. CD83 is an I-type lectin adhesion receptor that binds monocytes and a subset of activated CD8+ T cells [corrected]. J Immunol. 2001;166(6):3865–72.PubMed
131.
Zhou LJ, Tedder TF. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J Immunol. 1995;154(8):3821–35.PubMed
132.
Breloer M, Fleischer B. CD83 regulates lymphocyte maturation, activation and homeostasis. Trends Immunol. 2008;29(4):186–94.PubMed
133.
Akauliya M, Gautam A, Maharjan S, Park BK, et al. CD83 expression regulates antibody production in response to influenza A virus infection. Virol J. 2020;17(1):194.PubMedPubMedCentral
134.
Wu Y, Mao H, Ling MT, Chow KH, et al. Successive influenza virus infection and Streptococcus pneumoniae stimulation alter human dendritic cell function. BMC Infect Dis. 2011;11:201.PubMedPubMedCentral
135.
Ma N, Li X, Jiang H, Dai Y, et al. Influenza virus neuraminidase engages CD83 and promotes pulmonary injury. J Virol. 2021;95(3):10–128.
Metadata
Title
Immune response in influenza virus infection and modulation of immune injury by viral neuraminidase
Authors
Hongyu Jiang
Zongde Zhang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2023
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-023-02164-2

Other articles of this Issue 1/2023

Virology Journal 1/2023 Go to the issue

Research

Patch-clamp studies and cell viability assays suggest a distinct site for viroporin inhibitors on the E protein of SARS-CoV-2

Research

Safety and efficacy of the FAKHRAVAC compared with BBIBP-Corv2 against SARS-CoV-2 in adults: a non-inferiority multi-center trial

Research

Global molecular evolution and phylogeographic analysis of barley yellow dwarf virus based on the cp and mp genes

Retraction Note

Retraction Note to: Inhibition of Tomato Yellow Leaf Curl Virus (TYLCV) using whey proteins

Research

A polyvalent virosomal influenza vaccine induces broad cellular and humoral immunity in pigs

Research

Screening for viral pathogens in the gastrointestinal tract from cases of sudden unexpected death in infancy at the Tygerberg Medico-legal Mortuary
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits